AI narrative masks flat profit growth and margin squeeze
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade C
No prior FY27 guidance stated; cannot assess miss. Q1 delivered in line with call's narrative (soft macro, deal ramp delays) but numbers disappoint.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Strategic AI positioning and mega deal potential are real, but Q1 fundamentals are soft: profit growth stalled at 1% YoY, PAT margins compressed 220 bps, and management flagged margin suppression through Q3. Execution risk on mega deal (only half-quarter ramped, transition costs ate margins). Vertical concentration—HLS, MCS, TMT all declining—leaves only BFSI as growth engine.
₹1508.3 Cr
Revenue · +8.9% YoY₹183.8 Cr
Reported PAT · +1% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
YoY revenue growth 8.9%, QoQ 4% in INR terms
METDelivered: revenue 1508.3 Cr, YoY +8.9%, QoQ +4.0% confirmed
PAT margin 12.2%, contracted 220 bps sequentially
METPAT 183.8 Cr ÷ revenue 1508.3 Cr = 12.19%. Compression confirmed; major red flag on QoQ PAT -12.7%
Large deal contribution only transition-related in Q1, full ramp Q3–Q4
METBFSI +8.3% Q-o-Q; management withheld deal breakdown but BFSI growth confirmed. Ramp-up timing credible.
BFSI grew even excluding mega deal
PartialStated but not quantified. Core BFSI momentum plausible but unverified.
Operational leverage from 1,451 headcount adds (50% higher than Q4)
METDelivered gross addition confirmed in call; utilization +80 bps to 85.1%. Positive signal, but margins compressed despite.
Earnings quality
What changed since the last call
Vertical performance divergence widens
DowngradeBFSI +8.3% QoQ but HLS/MCS/TMT now in second quarter of decline. Portfolio concentration risk vs FY26 start-year diversification plan.
Margin outlook extended suppression
DowngradeQ1 PAT margins 12.2%, down 220 bps QoQ. CFO stated Q2–Q3 will be 'similar range' (12.2% ±), not recovery. Pushes profitability inflection to Q3 onwards vs Q2 hoped.
Order book narrative shift
NeutralDown to $149M (multi-qtr low) from $403M Q4, but management re-framed as high-quality (all-time high new-business ratio). Proposes 0.9–1.1x book-to-bill aspiration maintained, not raised. Tonal confidence vs numbers mismatch.
Large client headwind acknowledged
DowngradeManish flagged 'largest client might be more muted going forward' (i.e., slowdown persists). Previously unmentioned specific risk now in open.
The Q&A
Q&A was skeptical on order book lows and margin outlook. Analysts pressed on why book-to-bill aspiration remains 0.9–1.1x if verticals are leaking; Manish defended by noting mega deal distortion ($403M TCV skews metrics) and that sales force is being revamped for AI. CFO held firm on margin suppression through Q3 by design (growth priority). Management felt defensive on execution pace (Shradha asked if mega deal ramping ahead of plan; Manish clarified 'half quarter, transition only').
Mega deal / BFSI breakdown — Shradha Agrawal, Asian Markets Securities
PartialManish: Deal started mid-Feb (half-quarter), mostly transition costs. Won't disclose contribution. But BFSI grew even without it.
Order book / pipeline TCV — Shradha Agrawal, Asian Markets Securities
AnsweredManish: Correct, $150M ~. But new-business ratio all-time high. Q1 is seasonal. Prior quarter $400M bumper. Not concerned.
SME competitive intensity — Shradha Agrawal, Asian Markets Securities
AnsweredManish: Yes, intensity up. But large companies not built for SMB agility. 350 clients = limited bandwidth for SMB focus.
Vertical decline moderation — Nitin Padmanabhan, Investec India
PartialManish: Less bullish on Europe/MCS. Africa OK. TMT ex-largest client OK. HLS recovered 75% of drop, expect growth going forward. Pulkit: Mega deal skews book-to-bill; 0.9–1.1x aspiration maintained. Margins Q2–Q3 similar then recover.
Execution priorities & risks — Sucrit Patil, Eyesight Fintrade
AnsweredManish: (1) AI-native org, (2) AI for clients, (3) Mega deal ramp. Risks: macro, competition. But we're positioning for AI leadership.
Financial risks & mitigation — Sucrit Patil, Eyesight Fintrade
AnsweredPulkit: Margins depressed for growth (Q2–Q3 similar, then up). OCF-to-EBITDA strong ~70%+. DSO 75d (improved), payment terms stretching but OK. No major receivables issue.
Broad-based vertical decline — Sandeep Shah, Equirius Securities
PartialManish: No structural issue. Concentration risk reduced (added 4 $10M+ accounts). Environment has ups/downs. Focus on net new & farming.
Book-to-bill aspiration — Sandeep Shah, Equirius Securities
PartialManish: Mega deal is 1/3 revenue (would be $5–6B at Tier-1). Sales costs up, revamping force. Large client headwind muted. Apply 0.9–1.1x to $403M = your number. Focused on revenue growth and AI go-to-market.
Large deal pipeline & margins — Sandeep Shah, Equirius Securities
PartialManish: 23% pipeline is large deals, no mega deals. Difficult to give 3–4 qtr prognosis (AI world volatile). Q2 better than Q1 only. Gross margin down due to mega deal.
HLS vertical decline — Amit Chandra, HDFC Securities
AnsweredManish: Portfolio & client-specific. FDA slowdown hurt biotech. Primary: consolidation in 1–2 clients consolidated-out.
Guidance
No explicit FY27 revenue target; mega deal full ramp Q3–Q4
LowManish: 'Q2 will be better than Q1 is all I can say' (qualitative). Mega deal $210M (started mid-Feb) to ramp through year; transition-only Q1.
PAT margins Q2–Q3 similar to Q1 (~12.2%), then improve from Q3 onwards
MediumPulkit: Growth/SG&A investment priority for next 1–2 qtrs. Margins intentionally suppressed. Recovery Q3+ as deal ramps and leverage builds.
Scaled M&A targets $150–200M revenue range; 2–3 assets under review
MediumManish: Not seeking tuck-ins; looking at scaled assets. $317.5M cash available. 'Right time, pricing not absurd.' Timing: no specific date.
Risks the call surfaced
Mega deal execution
HighMega deal $210M (1/3 of revenue) only half-quarter ramping in Q1, mostly transition costs. Full ramp deferred to Q3–Q4. Pre-staffing ate 2% EBITDA; management cannot quantify ramp trajectory.
Vertical concentration risk
HighBFSI is sole growth driver (+8.3% QoQ). HLS, MCS, TMT all declining (−3.8%, −2.3%, −9.1% QoQ). Second consecutive quarter of broad-based weakness outside BFSI. Portfolio diversification plan unexecuted.
Margin compression extended
HighPAT margin 12.2% in Q1, down 220 bps QoQ. CFO stated Q2–Q3 margins will be 'similar range' due to SG&A/capability investments + mega deal ramp-up. Profitability recovery delayed to Q3+. Creates 3-quarter margin pressure while growth narrative dominates.
Order book weakness
MediumOrder book $149M is multi-quarter low vs $403M prior quarter. Analysts flagged as near-term signal of slowing deal creation. Management reframed as seasonal Q1 + high new-business quality (all-time high), but TCV velocity unproven.
Macro / large-client headwind
HighManish flagged 'largest client might be more muted going forward' (TMT −9.1% QoQ driven by this). Europe weakness in MCS. FDA slowdown impacting HLS biotech clients. Macro uncertainty cited repeatedly. These are structural, not cyclical risks if clients are consolidating or cutting capex.
AI platform adoption risk
MediumZensar launched ZenseAI.AgentMesh and multiple platform variants (QI, AssureAI, Guidewire, etc.). While examples (25%+ uplift, 40–60% savings) are impressive, they are primarily internal/proof-of-concept. Revenue contribution from AI products not yet quantified or material.
Management
Score 6/10. Clear and strategic on AI vision; candid on headwinds (TMT slowdown, HLS consolidation, Europe weakness). Evasive on mega deal contribution to BFSI and specific growth numbers. Track record mixed: mega deal ramping slower than hoped (half-quarter in Q1 vs implied faster ramp), cost inflation impacting margins, vertical declines widening despite portfolio diversification claims.
1 · Q2 FY27 (Sep 2026)
Mega deal ramp-up accelerates; management promised 'better than Q1' revenue
2 · Q3–Q4 FY27
Full weight of mega deal revenue appears; margins expected to recover from depressed Q2–Q3 levels
3 · Near term (next 2 qtrs)
HLS recovery expected (management cites 75% of drop recovered); MCS and TMT stabilization critical
Vertical concentration—HLS, MCS, TMT all declining—leaves only BFSI as growth engine.
Informational and educational content only. Not investment advice.